Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Amortization of Deferred Charges (2020 - 2023)

Historic Amortization of Deferred Charges for RxSight (RXST) over the last 4 years, with Q3 2023 value amounting to $4000.0.

  • RxSight's Amortization of Deferred Charges fell 9720.28% to $4000.0 in Q3 2023 from the same period last year, while for Jun 2024 it was $4000.0, marking a year-over-year decrease of 9929.82%. This contributed to the annual value of $287000.0 for FY2023, which is 4800.72% down from last year.
  • As of Q3 2023, RxSight's Amortization of Deferred Charges stood at $4000.0, which was down 9720.28% from $142000.0 recorded in Q2 2023.
  • In the past 5 years, RxSight's Amortization of Deferred Charges ranged from a high of $144000.0 in Q4 2022 and a low of $4000.0 during Q3 2023
  • Its 4-year average for Amortization of Deferred Charges is $106923.1, with a median of $132000.0 in 2021.
  • As far as peak fluctuations go, RxSight's Amortization of Deferred Charges soared by 84285.71% in 2021, and later crashed by 9720.28% in 2023.
  • Over the past 4 years, RxSight's Amortization of Deferred Charges (Quarter) stood at $44000.0 in 2020, then surged by 200.0% to $132000.0 in 2021, then rose by 9.09% to $144000.0 in 2022, then crashed by 97.22% to $4000.0 in 2023.
  • Its Amortization of Deferred Charges stands at $4000.0 for Q3 2023, versus $142000.0 for Q2 2023 and $141000.0 for Q1 2023.